Objective: Evaluation of the costs, effects and savings of three strategies for female fragile X premutation and full mutation carrier screening in the general population. Methods: We calculated the costs, effects and savings by using a general model for prenatal, preconceptional, and school carrier screening. Assumptions were based on literature data, expert opinions, prices and tariffs. Results: Prenatal screening will detect most carriers and will lead to the highest number of avoided fragile X syndrome patients. The costs per detected carrier are quite similar for all screening programmes (around USD 45,000). All screening strategies have a favourable cost-savings balance (USD 14 million for prenatal screening, USD 9 million for preconceptional screening and USD 2 million for school screening). Conclusions: From an economic point of view, there is no obstacle to fragile X screening. The decision to screen or not can (and should) therefore concentrate on discussion of medical, social, psychological and ethical considerations.
Mark F. Wildhagen, M.Sc.
Department of Public Health, Faculty of Medicine
Erasmus University Rotterdam, PO Box 1738
NL–3000 DR Rotterdam (The Netherlands)
Tel. +31 10 408 7714, Fax +31 10 436 6831, E-Mail email@example.com
Number of Print Pages : 12
Number of Figures : 3, Number of Tables : 5, Number of References : 65
Vol. 1, No. 1, Year 1998 (Cover Date: Released May 1998)
Journal Editor: L.P. ten Kate, Amsterdam
ISSN: 1422–2795 (print), 1422–2833 (Online)
For additional information: http://www.karger.com/journals/cmg
Article / Publication Details
Published online: 5/7/1998
Issue release date: May 1998
Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 0
ISSN: 1662-4246 (Print)
eISSN: 1662-8063 (Online)
For additional information: http://www.karger.com/PHG
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.